Seminars in Oncology
Volume 32, Issue 1 , Pages 103-112 , February 2005

Combined modality treatment for rectal cancer

  • Andrew X. Zhu

      Affiliations

    • Massachusetts General Hospital, Harvard Medical School, Boston, MA
    • ,
  • Christopher G. Willett

      Affiliations

    • Duke University Medical Center, Durham, NC
    • Corresponding Author InformationAddress reprint requests to Andrew X. Zhu, MD, PhD, Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA 02114

References 

  1. Jemal A , Tiwari RC , Murray T , et al.   Cancer statistics, 2004 . CA Cancer J Clin . 2004;54:8–29
  2. Billingham RP . Conservative treatment of rectal cancer. Extending the indications . Cancer . 1992;70:1355–1363
  3. Willett CG , Tepper JE , Kaufman DS , et al.   Adjuvant postoperative radiation therapy for rectal adenocarcinoma . Am J Clin Oncol . 1992;15:371–375
  4. Bleday R , Steele G . Current protocols and outcomes of local therapy for rectal cancer . Surg Oncol Clin North Am . 2000;9:751–758
  5. Brodsky JT , Richard GK , Cohen AM , et al.   Variables correlated with the risk of lymph node metastasis in early rectal cancer . Cancer . 1992;69:322–326
  6. Willett CG , Tepper JE , Donnelly S , et al.   Patterns of failure following local excision and local excision and postoperative radiation therapy for invasive rectal adenocarcinoma . J Clin Oncol . 1989;7:1003–1008
  7. Chakravarti A , Compton CC , Shellito PC , et al.   Long-term follow-up of patients with rectal cancer managed by local excision with and without adjuvant irradiation . Ann Surg . 1999;230:49–54
  8. Wong CS , Stern H , Cummings BJ . Local excision and post-operative radiation therapy for rectal carcinoma . Int J Radiat Oncol Biol Phys . 1993;25:669–675
  9. Fortunato L , Ahmad NR , Yeung RS , et al.   Long-term follow-up of local excision and radiation therapy for invasive rectal cancer . Dis Colon Rectum . 1995;38:1193–1199
  10. Wagman R , Minsky BD , Cohen AM , et al.   Conservative management of rectal cancer with local excision and postoperative adjuvant therapy . Int J Radiat Oncol Biol Phys . 1999;44:841–846
  11. Steele GD , Herndon JE , Bleday R , et al.   Sphincter-sparing treatment for distal rectal adenocarcinoma . Ann Surg Oncol . 1999;6:433–441
  12. Russell AH , Harris J , Rosenberg PJ , et al.   Anal sphincter conservation for patients with adenocarcinoma of the distal rectum (Long-term results of Radiation Therapy Oncology Group protocol 89-02) . Int J Radiat Oncol Biol Phys . 2000;46:313–322
  13. Blair S , Ellenhorn JD . Transanal excision for low rectal cancers is curative in early-stage disease with favorable histology . Am Surg . 2000;66:817–820
  14. Chari RS , Tyler DS , Anscher MS , et al.   Preoperative radiation and chemotherapy in the treatment of adenocarcinoma of the rectum . Ann Surg . 1995;221:778–786
  15. Minsky BD , Cohen AM , Kemeny N , et al.   Enhancement of radiation-induced downstaging of rectal cancer by fluorouracil and high-dose leucovorin chemotherapy . J Clin Oncol . 1992;10:79–84
  16. Minsky BD , Cohen AM , Enker WE , et al.   Sphincter preservation with preoperative radiation therapy and coloanal anastomosis . Int J Radiat Oncol Biol Phys . 1995;31:553–559
  17. Mendenhall WM , Bland KI , Copeland EM , et al.   Does preoperative radiation therapy enhance the probability of local control and survival in high-risk distal rectal cancer? . Ann Surg . 1992;215:696–705
  18. Myerson RJ , Michalski JM , King ML , et al.   Adjuvant radiation therapy for rectal carcinoma (Predictors of outcome) . Int J Radiat Oncol Biol Phys . 1995;32:41–50
  19. Rich TA , Skibber JM , Ajani JA , et al.   Preoperative infusional chemoradiation therapy for stage T3 rectal cancer . Int J Radiat Oncol Biol Phys . 1995;32:1025–1029
  20. Roh MS , Petrelli N , Wieand S , et al.   Phase III randomized trial of preoperative versus postoperative multimodality therapy in patients with carcinoma of the rectum (NSABP R-03) . Proc Am Soc Clin Oncol . 2001;20:123a; (abstr 490)
  21. Allal AS , Bieri S , Pelloni A , et al.   Sphincter-sparing surgery after preoperative radiotherapy for low rectal cancers (Feasibility, oncologic results and quality of life outcomes) . Br J Cancer . 2000;82:1131–1137
  22. Bosset JF , Magnin V , Maingon P , et al.   Preoperative radiochemotherapy in rectal cancer (Long-term results of a phase II trial) . Int J Radiat Oncol Biol Phys . 2000;46:323–327
  23. Sauer R . Adjuvant versus neoadjuvant combined modality treatment for locally advanced rectal cancer (First results of the German Rectal Cancer Study (CAO/ARO/AIO-94)) . Int J Radiat Oncol Biol Phys . 2003;57:S124–S125
  24. Gastrointestinal Tumor Study Group . Prolongation of the disease-free interval in surgically treated rectal carcinoma . N Engl J Med . 1985;312:1465–1472
  25. Krook JE , Moertel CG , Gunderson LL , et al.   Effective surgical adjuvant therapy for high-risk rectal carcinoma . N Engl J Med . 1991;324:709–715
  26. Fisher B , Wolmark N , Rockette H , et al.   Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer (Results from NSABP protocol R-01) . J Natl Cancer Inst . 1988;80:21–29
  27. NIH Consensus Conference . Adjuvant therapy for patients with colon and rectal cancer . JAMA . 1990;264:1444–1450
  28. Gastrointestinal Tumor Study Group . Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum . J Clin Oncol . 1992;10:549–557
  29. O’Connell MJ , Martenson JA , Wieand HS , et al.   Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery . N Engl J Med . 1994;331:502–507
  30. Tepper JE , O’Connell MJ , Petroni GR , et al.   Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer (Initial results of Intergroup 0114) . J Clin Oncol . 1997;15:2030–2039
  31. Tepper JE , O’Connell M , Niedzwiecki D , et al.   Adjuvant therapy in rectal cancer (Analysis of stage, sex, and local control—Final report of intergroup 0114) . J Clin Oncol . 2002;20:1744–1750
  32. Smalley SR , Benedetti J , Williamson S , et al.   Intergroup 0144—Phase III trial of 5-FU based chemotherapy regimens plus radiotherapy (XRT) in postoperative adjuvant rectal cancer. Bolus 5-FU vs prolonged venous infusion (PVI) before and after XRT + PVI vs bolus 5-FU + leucovorin (LV) + levamisole (LEV) before and after XRT + bolus 5-FU + LV . Proc Am Soc Clin Oncol . 2003; (abstr 1006)
  33. Miwa M , Ura M , Nishida M , et al.   Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue . Eur J Cancer . 1998;34:1274–1281
  34. Schuller J , Cassidy J , Dumont E , et al.   Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients . Cancer Chemother Pharmacol . 2000;45:291–297
  35. Hoff PM , Ansari R , Batist G , et al.   Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer (Results of a randomized phase III study) . J Clin Oncol . 2001;19:2282–2292
  36. Van Cutsem E , Twelves C , Cassidy J , et al.   Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer (Results of a large phase III study) . J Clin Oncol . 2001;19:4097–4106
  37. Dunst J , Reese T , Sutter T , et al.   Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer . J Clin Oncol . 2002;20:3983–3991
  38. Kim JS , Cho MJ , Song KS , et al.   Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer . Int J Radiat Oncol Biol Phys . 2002;54:403–408
  39. Androulakis N , Kouroussis C , Kakolyris S , et al.   Phase I study of capecitabine combination with radiotherapy as adjuvant treatment for operable rectal cancer . Proc Am Soc Clin Oncol . 2002; (abstr 2297)
  40. Ngan S , Zalcberg J , Kell A , et al.   A phase I study of capecitabine combined with radiotherapy for locally advanced potentially operable rectal cancer . Proc Am Soc Clin Oncol . 2001; (abstr 591)
  41. Cunningham D , Pyrhonen S , James RD , et al.   Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer . Lancet . 1998;352:1413–1418
  42. Rougier P , Van Cutsem E , Bajetta E , et al.   Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer . Lancet . 1998;352:1407–1412
  43. Saltz LB , Cox JV , Blanke C , et al.  Irinotecan Study Group   Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer . N Engl J Med . 2000;343:905–914
  44. Douillard JY , Cunningham D , Roth AD , et al.   Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer (A multicentre randomised trial) . Lancet . 2000;355:1041–1047
  45. Minsky BD , O’Reilly E , Wong D , et al.   Daily low-dose irinotecan (CPT-11) plus pelvic irradiation as preoperative treatment of locally advanced rectal cancer . Proc Am Soc Clin Oncol . 1999; (abstr)
  46. Mitchell EP , Anne P , Fry R , et al.   Combined mordality therapy of locally advanced or recurrent adenocarcinoma of the rectum (Report of a pPhase I trial of chemotherapy (CT) with CPT-11, 5-FU and concomitant irradiation (RT)) . Proc Am Soc Clin Oncol . 2001; (abstr 519)
  47. Mehta VK , Cho C , Ford JM , et al.   Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer . Int J Radiat Oncol Biol Phys . 2003;55:132–137
  48. de Gramont A , Figer A , Seymour M , et al.   Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer . J Clin Oncol . 2000;18:2938–2947
  49. Giacchetti S , Perpoint B , Zidani R , et al.   Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer . J Clin Oncol . 2000;18:136–147
  50. Andre T , Louvet C , Raymond E , et al.   Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen . Ann Oncol . 1998;9:1251–1253
  51. Brienza S , Bensmaine MA , Soulie P , et al.   Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/− FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC) (Results from the European compassionate-use program) . Ann Oncol . 1999;10:1311–1316
  52. Maindrault-Goebel F , de Gramont A , Louvet C , et al.  Oncology Multidisciplinary Research Group (GERCOR)   Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer . Ann Oncol . 2000;11:1477–1483
  53. Maindrault-Goebel F , de Gramont A , Louvet C , et al.   High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7) . Eur J Cancer . 2001;37:1000–1005
  54. Martoni A , Mini E , Pinto C , et al.   [Oxaliplatin: Combinations with thymidylate synthetase inhibitors: two consecutive phase II studies] . Tumori . 2001;87:A25–A26
  55. Chau I , Webb A , Cunningham D , et al.   Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer . Br J Cancer . 2001;85:1258–1264
  56. Rothenberg ML , Oza AM , Bigelow RH , et al.   Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin (Interim results of a phase III trial) . J Clin Oncol . 2003;21:2059–2069
  57. Goldberg RM , Sargent DJ , Morton RF , et al.   A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer . J Clin Oncol . 2004;22:23–30
  58. Freyer G , Bossard N , Romestaing P , et al.   Addition of oxaliplatin to continuous fluorouracil, l-folinic acid, and concomitant radiotherapy in rectal cancer (The Lyon R 97-03 phase I trial) . J Clin Oncol . 2001;19:2433–2438
  59. Gerard JP , Chapet O , Nemoz C , et al.   Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen (The Lyon R0-04 phase II trial) . J Clin Oncol . 2003;21:1119–1124
  60. Aschele C , Friso ML , Pucciarelli S , et al.   A phase I-II study of weekly oxaliplatin (OXA), 5-fluorouracil (FU) continuous infusion (CI) and preoperative radiotherapy (RT) in locally advanced rectal cancer (LARC) . Proc Am Soc Clin Oncol . 2002; (abstr 527)
  61. Sebag-Montefiore D , Glynne-Jones R , Falk S , et al.   Preoperative radiation and oxaliplatin in combination with 5-fluorouracil (5-FU) and low-dose leucovorin (LV) in locally advanced rectal cancer . Proc Am Soc Clin Oncol . 2002; (abstr 580)
  62. Roca E , Carraro S , Cartelli C , et al.   Radiochemotherapy with short daily infusion of low dose oxaliplatin, leucovorin and 5FU in T3-T4 unresectable rectal cancer. A phase II IATTGI study . Proc Am Soc Clin Oncol . 2002; (abstr 2204)
  63. Williams CS , Mann M , DuBois RN . The role of cyclooxygenases in inflammation, cancer, and development . Oncogene . 1999;18:7908–7916
  64. Marnett LJ . Aspirin and the potential role of prostaglandins in colon cancer . Cancer Res . 1992;52:5575–5589
  65. Oshima M , Dinchuk JE , Kargman SL , et al.   Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2) . Cell . 1996;87:803–809
  66. Milas L , Kishi K , Hunter N , et al.   Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme . J Natl Cancer Inst . 1999;91:1501–1504
  67. Kishi K , Petersen S , Petersen C , et al.   Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor . Cancer Res . 2000;60:1326–1331
  68. Tsujii M , Kawano S , DuBois RN . Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential . Proc Natl Acad Sci U S A . 1997;94:3336–3340
  69. Masferrer JL , Koki A , Seibert K . COX-2 inhibitors. A new class of antiangiogenic agents . Ann N Y Acad Sci . 1999;889:84–86
  70. Gorski DH , Mauceri HJ , Salloum RM , et al.   Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin . Cancer Res . 1998;58:5686–5689
  71. Mauceri HJ , Hanna NN , Beckett MA , et al.   Combined effects of angiostatin and ionizing radiation in antitumour therapy . Nature . 1998;394:287–291
  72. Ferrara N , Davis-Smyth T . The biology of vascular endothelial growth factor . Endocr Rev . 1997;18:4–25
  73. Presta LG , Chen H , O’Connor SJ , et al.   Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders . Cancer Res . 1997;57:4593–4599
  74. Gordon MS , Margolin K , Talpaz M , et al.   Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer . J Clin Oncol . 2001;19:843–850
  75. Margolin K , Gordon MS , Holmgren E , et al.   Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer (Pharmacologic and long-term safety data) . J Clin Oncol . 2001;19:851–856
  76. Hurwitz H , Fehrenbacher L , Cartwright T , et al.   Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC) (Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC) . Proc Am Soc Clin Oncol . 2003; (abstr 3646)
  77. Willett CG , Boucher Y , di Tomaso E , et al.   Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer . Nat Med . 2004;10:145–147
  78. Goldstein NS , Armin M . Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma (Implications for a standardized scoring system) . Cancer . 2001;92:1331–1346
  79. Salomon DS , Brandt R , Ciardiello F , et al.   Epidermal growth factor-related peptides and their receptors in human malignancies . Crit Rev Oncol Hematol . 1995;19:183–232
  80. Cunningham D , Humblet S , Siena S , et al.   Cetuximab (C225) alone or in combination with irinotecan CCPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC) . Proc Am Soc Clin Oncol . 2003; (abstr 1012)
  81. Saltz L . Cetuximab (IMC-C225) plus irinotecan (PT-11) is active in CPT011-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR) . Proc Am Soc Clin Oncol . 2001; (abstr 7)
  82. Saltz L . Single agent IMC-C225 (Eribitux) has activity in CPT-11-refractory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR) . Proc Am Soc Clin Oncol . 2002; (abstr 504)
  83. Volter V , Stupp R , Matter M , et al.   Preoperative hyperfractionated accelerated radiotherapy (HAER) and concomitant CPT-11 in rectal carcinoma. A phase I/II study . Proc Am Assoc Cancer Res . 2001; (abstr 2254)

PII: S0093-7754(04)00461-0

doi: 10.1053/j.seminoncol.2004.09.032

Seminars in Oncology
Volume 32, Issue 1 , Pages 103-112 , February 2005

Article Tools